Motor Improvement-Related Regional Cerebral Blood Flow Changes in Parkinson’s Disease in Response to Antiparkinsonian Drugs
Table 1
Characteristics of the 30 PD patients and the subgroups according to the presence of dementia.
Total 30 PD patients
PD-ND subgroup
PD-D subgroup
n (gender, men: women)
30 (19 : 11)
16 (9 : 7)
14 (10 : 4)
Age when examined (years)
73.5 (SD 8.2)
71.3 (SD 8.5)
76.1 (SD 6.9)
Disease duration (years)
6.4 (SD 6.3)
4.6 (SD 3.1)
8.5 (SD 8.1)
Mean MDS-UPDRS total score in the off-stage (points)
65.4 (SD 31.9)
54.6 (SD 22.3)
78.1 (SD 36.2)
Mean MDS-UPDRS part III score in the off-stage (points)
31.8 (SD 17.0)
27.6 (SD 12.8)
36.6 (SD 19.7)
Daily dosage of antiparkinsonian drugs (LED, mg)
445.1 (SD 241.6)
469.5 (SD 252.3)
417.1 (SD 225.4)
Hoehn and Yahr stage in the off-stage (points)
2.6 (SD 0.9)
2.4 (SD 0.8)
2.7 (SD 0.9)
MMSE, total score (points)
25.2 (SD 3.8)
28.3 (SD 1.4)
21.6 (SD 2.3)†
M/C (%)
50
50
50
Hallucination (%)
47
13
86†
Depression and anxiety (%)
67
69
64
Orthostatic hypotension (%)
63
69
57
†Significant difference between the two subgroups (). LED, levodopa equivalent dose; M/C, motor complications; MDS-UPDRS, Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination; PD, Parkinson’s disease, PD-D, PD with dementia; PD-ND, PD without dementia; SD, standard deviation.
